USE OF BACTERIA ENDOWED WITH ARGININE DEIMINASE TO INDUCE APOPTOSIS AND/OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL OR DIETETIC COMPOSITIONS CONTAINING SUCH BACTERIA

Abstract: Disclosed is the use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction, and pharmaceutical or dietetic compositions containing such bacteria. Also inclosed is a strain of Lactobacillus brevis highly endowed with arginine deiminase.

Description: Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria The present invention concerns the use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction, and pharmaceutical or dietetic compositions which contain such bacteria. The invention also concerns a strain of Lactobaci llus brevis which is highly endowed with arginine deiminase. The balance between the cell population in an organism can be controlled by way of regulating the rate of proliferation or differentiation or death of the constituent cells (Collins. M. K. L. et al. A. Trends Bioche . Sci. 18:307. 1993). Cell death during embryogenesis. metamorphosis, hormone-dependent tissue atrophy and the normal turnover of the tissues is referred to as "programmed cell death". For the large part that event takes place by way of "apoptosis". a process which is characterised by condensation and segmentation of the nucleus, condensation and fragmentation of the cytoplasm and often fragmentation of the chromosomic DNA into nucleosoal units (Schwartz. L. M. et al Immunol . Today 14:582. 1993). Apoptosis in the development of vertebrates often occurs when the cells do not receive the extracellular survival signals necessary to suppress an intrinsic cell suicide programme; the survival factors can be produced by the surrounding cells of different type (paracnne mechanism) or of the same type (autocπne mechanism). Apoptosis occurs during embryonic development in particular in complex organs where a given cell sub-population is killed For example many neurons move in the brain during development, just as auto-reactive T lymphocytes are eliminated in the interior of the thymus In an adu.lt apoptosis occurs in particular in tissues which are suDjected to reversible expansion as in the hormone-dependent cells of the breast and the prostate gland after removal of the hormone or following cytokme-dependent expansion of the haemopoietic cells of the bone marrow The modifications which occur in the cell in the course of apoptosis have been widely studied and described (Cohen. J. J. et al Lab Clin Hed 124:761. 1994). Apoptosis is clearly different from necrosis which corresponds to the modifications which occur when cell death derives from cell damage. In necrosis in fact the damaged cells swell up and burst, releasing their mtracellular content which is toxic in relation to other cells of the tissue, and triggering off an inflammatory response. In contrast phagocytosis of the apoptotic bodies is so fast as not to induce dispersion of the cellular contents in the extracellular space which otherwise would cause peπlesional phlogosis typical of necrosis. Recent experimental evidence indicates that alterations in cell survival contribute to the pathogenesis of many human diseases including cancer. viral infections. auto-immune diseases, neurovegetative disorders and AIDS (Thompson. C. B. Science 2671456. 1995). A treatment aimed at specifically altering apoptosis can have the potential to modify the natural progression of some of those diseases Both chemotherapy agents and radiation induce the death of tumour cells primarily causing damage to the DNA which in turn causes cell suicide In addition many tumours conserve some of the physiological cell death control systems which are characteristic of the cells from which they originate For example cancer of the prostate and cancer of the breast are respectively androgen- and oestrogen-dependent. Therefore anti-androgemc therapy in the treatment of cancer of the prostate gland or removal of oestrogens by means of anti -oestrogens such as tamoxifen in the course of breast cancer are fundamental and universally accepted procedures Both those methods induce apoptosis in the tumour cells which are otherwise respectively dependent for their survival on androgens or oestrogens. In addition the beneficial effects of glucocorticoids observed in subjects with lymphoidal leukaemia can be attributed to the induction of apoptosis: other substances used for chemotherapy of cancer such as cyclophosphamide. metotrexate. etoposide and cisplatin induce apoptosis of tumour cells (Thatte. U. et al Apoptosis. Drugs 54:511. 1997). Previous studies have shown that lactic bacteria present in foods and/or in dietetic/pharmaceutical formulations can cause transitory colonisation of the intestine and have beneficial effects. Survival during the intestinal transit or adhesion to the epithelium seem to be important for modifying the immune response of the host (Schiffrin. E. J. et al Am. J. Clin. Nutr. 66: 515S. 1997). The potentially beneficial effects of lactic bacteria include protection from enteric infections, stimulating the secretion of IgA. and inhibition of the growth of intestinal carcinoma, strengthening the activity of IgA. T- cells and macrophages (Perdigon. G. et al J. Dairy Sci . 78:1597. 1995). In vitro, lactic bacteria have revealed a capacity to stimulate the production of alpha TNF. interleukm (IU-6 and IL-10 on the part of human mononuclear cells, even to an extent greater than that revealed when using lipopolysacchande (LPS) as a stimulating agent, confirming a potentiating action on non-specific immunity of the host (Miettmen. M. et al Infect. Immun. 64:5403. 1996). Still m vitro, lactic bacteria have demonstrated a capacity to absorb mutagemc substances present in cooked foods, confirming the observation that the administration of lactobacilli in man reduces the excretion of mutagemc substance after the mgestion of fried meat and thus the risk of cancer of the colon (Lidbeck, A. et al Eur. J. Cancer Prev. 1:341. 1992). Experiments conducted with fermented milk with Bi fidobactenum mfantis. Bifidobactenum bi fiόum, Bi fidobactenum ammalis. Lactobaci llus acidophi lus, or Lactobaci l lus paracasei on the growth of breast tumour cells MCF7 have demonstrated that the various fermented milks are capable, even if to varying degrees, of inhibiting the growth of tumour cells. The anti-proliferative effect cannot be correlated to the presence of the bacteria in the fermented milk., to the milk or to the fractions thereof; the hypothesis is for the presence of a soluble compound produced ex novo from the lactic bacteria during fermentation of the milk or microbial transformation of some components of the milk into a biologically active form (Biffi. A. et al Nutr. Cancer 28:93. 1997). Many micro-organisms use arginine as a source of carbon, nitrogen and energy. Arginine deiminase transforms arginine in the presence of water into citrulline and ammonia. That enzymatic procedure has been encountered in a variety of pathogenic or potentially pathogenic bacteria such as Pseudomonas sp and Baci l lus sp. and in some types of mycoplasms. It has been demonstrated that this system plays a part in oral ecology, in protecting less acid-tolerant organisms during the fall in the pH to 4, or even lower values, in dental plaque, during glycolysis caused by bacteria which are more resistant to acidity (Curran. T. M. Appl . Environ. Microbio. 61:4494. 1995). Studies have been conducted on arginine deiminase which can be obtained from mycoplasms. to be used as a cure for cancer (Takaku. H. et al Jpn. J. Cancer Res. 1:840. 1995). Mycoplasms are micro-organisms which are similar to bacteria which, unlike the latter, lack a cell wall and the genome of which is around 1/6 of that of E. coli : however they can be pathogenic for man. animals and for plants and in addition they cannot be easily handled due to the absence of a cell wall. Purification was thus implemented in respect of the enzyme arginine deiminase which can be obtained from mycoplasms. which behaves like an immunogen and which is not free from undesired effects if used m vivo (McGarπty, J. G. et al US-A-5372942). Other micro-organisms endowed with arginine deiminase (such as for example Pseudomonas sp and Baci l lus sp) cannot be used by virtue of their potential pathogemcity and pyrogemcity We have now surprisingly found that some bacteria are rich in arginine deiminase. in particular some Gram-positive bacteria and some Gram-negative bacteria, and also some strains of lactic bacteria, in particular of the species Lactobaci l lus brevis or Lactobaci l lus fermentu . more particularly the strain of Lactobaci l lus brevis referred to as CD2 deposited with the DSM - Deutsche Sammlung von Mikroorgamsmen und Zellkulturen GmbH, Brunswick. Germany, under the access number DSM 11988. are capable of inducing apoptosis and can therefore be used for prevention or therapy in respect of clinical situations characterised by insufficient or absent apoptosis or by inflammation. The above-mentioned bacteria have surprisingly shown an arginine deiminase capable of inducing apoptosis and they can be used as such or after suitable lyophilisation or also after somcation Indeed in accordance with the present invention the bacteria in question can be live or sonicated and the level of concentration can fluctuate from IxlO 1 CFU to lxlO 13 CFU per gram of composition, according to the desired effect and the amount of arginine deiminase which they have The same bacterial strains can be used to reduce or terminate an inflammatory reaction caused by nitric oxide (NO) NO which is synthesised from L-argimne by means of nitric oxide synthase (NOS) is an intra- and intercellular messenger with numerous biological actions. Alterations in the level of synthesis of NO are at the basis of numerous other physiopathological conditions such as arterial hypertension, renal insufficiency, septic shock, vasodilation induced by hypoxia. vasospasm resulting from subarachnoid haemorrhage, neuronal destruction in vascular infarction and other neurodegenerative conditions, chronic inflammatory pathologies, anaphylaxis and immunodeficiency Arginine deiminase converts arginine into citrulline and NH3 without the production of mtπc oxide and can thus have an anti -inflammatory and curative or remedial effect, for example in intestinal ma1absorption and pancreatic insufficiency with modulation for example of the metabolic and/or nutritional state of the subject An effect which is referred to by way of non-1 lmiting example can be that of reducing the levels of oxalates and/or phosphates in blood and urine. Non-1 imiting examples of diseases or disorders which can be treated and/or prevented by using bacteria which are rich in arginine deiminase are tumours in general in particular colon-rectal cancer, cancer of the liver, glioae, neuroblastomae. squamocellular oral carcinoma, lymphoid tumours, cancer of the prostate gland, cancer of the bladder, cancer of the breast, cancer of the pleura and the peritoneum, serious myasthenia. systemic lupus erytheatosus. and other auto-immune diseases including those of the thyroid, diseases characterised by acute and/or chronic inflammatory processes. bronchial asthma, intestinal inflammatory diseases, gastrites. duodenites. gastric ulcers, duodenal ulcers, pneumonias and pleurisies, infections from adenovirus. baculovirus and in general supported by a viral agent, diseases characterised by acute and/or chronic inflammatory and/or degenerative processes of the central and/or peripheral nervous system, pancreatites, endomyocardites and ischaeic damage (myocardiac. retinal, cerebral and renal), urolithiases. nephrocalcinoses, hyperoxaluria. hyperphosphaturia. nephroalteration in the systemic and/or district arterial and/or venous pressure such as portal hypertension, vaginoses and vagimtes. procto-haemerrhoidal inflammations, prostates, sinusites and otites. conjunctivites. gingivites. penodontopathy. anaphylactic phenomena and immunodeficiencies. Such micro-organisms which are rich in arginine deiminase can be used individually or in combination with each or with other lactic bacteria such as Lactobaci l lus acidophi lus. Lactobaci l lus buchnen . Lactobaci llus casei . Lactobaci l lus catenaforme. Lactobaci llus cellobiosus. Lactobaci llus cnspatus. Lactobaci l lus curvatus. Lactobacil lus delbrueckn . Lactobaci llus ensenn , Lactobacillus leichmami. Lactobacillus mwutus Lactobacillus plantarum. Lactobacillus rogosae. Lactobacillus salivanus. Bifidobactenum adolescent! s Bifidobactenum angulatum Bifidobactenum bifidum. Bifidobactenum breve. Bifidobactenum catenulatum. Bifidobactenum dentiu Bifidobactenum enksonn Bifidobactenum mfantis. Bifidobactenum longum. Bifidobactenum plantarum. Bifidobactenum pseudo-catenulatum. Bifidobactenum pseudolongum. Streptococcus lactis. Streptococcus raffmolactis Streptococcus thermophilus. Acidammococcus fer enta, Cytophaga fermentans. Rhodoferax fer entans, Cellulomonas fermentans and Zymomonas mobilis Still in accordance with the present invention the bacteria can be used in association with arginine deiminase, sphmgomyelinase or other enzymes. with cortisone. anti- inflammatory, immuno-modulant. cytostatic. immunological. endocπnological . vascular, anaesthetic. and vasodilatory drugs, growth factors, cytokmes. ceramides. vitamins and minerals, lipids. ammo acids and carbohydrates, formulations for enteric use and dietetic, prebiotic or probiotic supplements, and with excipients commonly used in the pharmaceutical industry or in the foodstuffs/dietetic field. The preferred form of administration is orally but it is not limitative in relation to possible topical, rectal, nasal or parenteral administration The composition of the invention will thus be in the form of pills or tablets, capsules, globuli. suppositories, emulsions, suspensions, stick-on plasters, creams, ointments, sprays, collyπa. collutoπa or dentifrices. The following examples which are set forth by way of non-1 imiting illustration will illustrate the present invention in greater detail Example 1 Induction of apoptosis in various cellular systems Cells used 1 Normal PBL (human peripheral blood lymphocytes) HS27 (normal human fibroblasts) HaCaT (eternalised normal human keratinocytes) 2 Tumoral Jurkat (human T leukaemia) P815 (muπne mastocytoma) J744 (muπne tumoral macrophages) The cells were cultivated in suitable medium with serum (10X) at 37°C (5SC0_) for 18-72 hours in the presence or absence of sonicated preparations in buffered solution of phosphates (PBS) of L. brevis (final concentration in the cellular suspensions: 100 mg/10 ml). At the end of the incubation operation the cells were counted and vitality determined on the basis of exclusion of the dye tπpan blue. Possible induction of death by apoptosis in the cells treated with the bacteria was determined on the basis of: - morphology under an optical microscope after colouring with haematoxylin/eosin. - colouring with acπdine orange/ethidium bromide detected by means of fluorescence microscopy and cytofluoπmetry. and detection of DNA laddering by means of agarose gel electrophoresis of the DNA. Table 1 Apoptosis (%) Controls L brevis (CD2) PBL 0 0 HS27 0 0 HaCaT 0 0 Jurkat 2-3 15-20 P815 0 1-3 J744 0 1-3 The above-reported results indicate clearly that treatment for 14- 18 hours with sonicated bacteria of the invention determines the induction of significant levels of apoptosis in tumoral cells, while not giving rise to any effect on the normal cell systems analysed Example 2 Demonstration of the presence of arginine deiminase in bacterial strains The activity of arginine deiminase in some bacterial strains was determined on the basis of conversion in an aqueous solution of radio- marked arginine into citrulline and NH 3 The presence of suitable inhibitors (L-N-mtro-argimne methyl ester HC1 and L-valine) capable of specifically inhibiting other enzymes which effect conversion of the arginine (nitric oxide synthase and arginase respectively) made it possible to attribute the enzymatic activity determined to the arginine deiminase and not to other enzymes In addition the use of a specific inhibitor in respect of arginine deiminase (formamidine) made it possible to confirm the soundness of the results 10 Tabl e 2 Activity of arginine deiminase (expressed as pmol of radioactive citrulline produced/mq bacterial proteins per minute Bacterial strain pmol citrulline/mg proteins/ππn L . brevis CD2 672 L . fermentu 046 L casei 013 L . acidophi lus 0002 L . plantarum 005 B. bi fidum 0.03 S. thermophi lus 0.020 Bacterial strains are considered as useful for the purposes of the present invention, which have values of greater than ON pmol citrulline/mg bacterial proteins/min The presence of inhibitors of nitric oxide synthase (L-ΝAME. L- mtromonomethyl arginine) or arginase (L-valine) did not in any way influence the enzymatic activity in regard to conversion of arginine to citrulline, thus making it possible to attribute the generation of citrulline observed with the various bacteria to the arginine deiminase. In addition the absence in the analysis system of calcium and cal odulin which are indispensable in terms of the activity of the constituent nitric oxide synthase did not in any way modify the activity in terms of conversion of the arginine on the part of bacteria, further confirming that the enzyme responsible for the latter is arginine deiminase The results set out hereinafter demonstrate that the activity of arginine deiminase encountered in the bacteria in question was further capable of completely inhibiting both the activity of constituent nitric oxide synthase (Ν0S) and that of inducible Ν0S. probably because the presence thereof involves deprivation of the substrate (arginine) of the various forms of nitric oxide synthase For that purpose rat cerebellum extracts and rat peritoneal macrophages 11 stimulated in vitro with lipopolysacchande of E. coli (100 mg/ml) and mterferon (100 U/ml) respectively were used as positive controls for constituent NOS and for inducible NOS Table 3 Activity of constituent and mducible nitric oxide synthase and arginine deiminase Sample Citrulline (pmol/5 micro!itres) Cerebellum 0.24 Cerebellum + L-NAME 0.01 Cerebellum + calcium chelatmg agent (EGTA) 0.01 Cerebellum more inhibitor of calmodulm (W13) 0.01 Cerebellum + L. brevis CD2 (5 micrograms) 0J2 Cerebellum + L. brevis CD2 + L-NAME 0.8 Cerebellum + L. brevis CD2 + EGTA 0J4 Cerebellum + L. brevis CD2 + W13 0J6 Cerebellum + L. fermentu (30 rrπcrogrammes) 0.38 Cerebellum + L. fermentum + L-NAME 0.4 Cerebellum + L. fermentum + EGTA 0.4 Cerebellum + L. fermentum + W13 0.39 Untreated macrophages 0 Macrophages + LPS + IFN 0.32 Macrophages + LPS + IFN + L-NAME 0 Macrophages + L. brevis CD2 (5 micrograms) 0J6 Macrophages + L. brevis CD2 + L-NAME 0J8 Macrophages + LPS + IFN + L. brevis CD2 0.81 Macrophages + LPS + IFN + L. brevis CD2 + L-NAME 0.82 Macrophages + L. fermentum (30 micrograms) 0.4 Macrophages + L. fermentum + L-NAME 0.41 Macrophages + LPS + IFN + L. fermentum 0.42 Macrophages + LPS + IFN + L. fermentum + L-NAME 0.4 12 It seems to be evident that not all the bacteria have an enzymatic activity in respect of arginine deiminase of a significant level for the purposes of the present invention (Table 2) and that the strains which are endowed therewith inhibit both constituent NOS and mducible NOS. as is confirmed by the persistent presence. of high values of citrulline even in the presence of specific inhibitors of the two types of NOS (Table 3). Example 3 4 patients were treated, suffering from pouchitis. a non-specific inflammation of the π leal reservoir, which is most frequently complicated in the long term by the occurrence of ileo-ano-anastomosis for ulcerative colitis. It has recently been suggested that pouchitis is the result of inflammatory NO-mediated damage. The subjects, all volunteers, were treated for 2 months with a lyophilised preparation of L. brevis CD2 at a concentration of 5xl0 10 CFU/gr, by mouth, at a dosage of 6 g/day. Before and after the treatment a biopsy sample was taken from the mucous membrane of the pouch, which was subjected to homogenisation and then to dosage of the citrulline by means of analysis of the conversion of radio-marked arginine into citrulline. Table 4 Effect of the treatment with CD2 on the activity of inducible nitric oxide synthase in intestinal biopsies of patients with pouchitis Citrulline (pmol/mg proteins/min) Patients TO Tl 1 2.95 0.89 2 1.15 0.56 3 0.56 0.5 4 0.47 0.28 5 0.7 0.5 13 The treatment with CD2 afforded a significant reduction in the levels of activity of inducible nitric oxide synthase.

Claims: 14 CLAIMS 1. A strain of bacteria characterised by an activity of arginine deiminase, expressed as picomols αtrullme/mg bacterial proteins/min, of not less than 0.1. and their descendants, mutants and derivatives which retain said activity. 2. A strain according to claim 1 selected from lactic bacteria. 3. A strain according to claim 2 selected from Lactobaci l lus brevis. Lactobaci l lus fermentum and Lactobaci l lus casei . 4. A strain according to claim 3 which is the strain Lactobaci l lus brevis CD2 deposited with the DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. Brunswick, Germany, under the access number DSM 11988. 5. Use of bacteria endowed with arginine deiminase to prepare a pharmaceutical or dietetic composition capable of inducing apoptosis and/or reducing an inflammatory reaction and/or producing a curative effect in intestinal alabsorption and pancreatic insufficiency with modulation of the metabolic and/or nutritional state of the subject to be treated. 6. Use according to claim 5 wherein the bacteria are Gram- positive bacteria. 7. Use according to claim 5 wherein the bacteria are Gram- negative bacteria. 8. Use according to claim 5 wherein the bacteria are lactic bacteria. 15 9. Use according to claim 8 wherein the lactic bacteria are selected from the species Lactobaci l lus brevis. Lactobaci l lus fermentum and Lactobaci l lus casei . 10. Use according to claim 9 wherein the lactic bacteria belong to any one of the strains according to claim 1 or claim 2. 11. Use according to claim 9 wherein the lactic bacteria belong to the strain Lactobaci l lus brevis CD2 deposited with the DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. Brunswick, Germany, under the access number DSM 11988. 12. Use according to any one of claims 5 to 11 in the prevention and treatment of tumours in general and in particular colon-rectal cancer, cancer of the liver, gliomae. neuroblastomae. squamocellular oral carcinoma, lymphoid tumours, cancer of the prostate gland, cancer of the bladder, cancer of the breast, cancer of the pleura and the peritoneum, serious myasthema. systemic lupus erythematosus . and other auto-immune diseases including those of the thyroid, diseases characterised by acute and/or chronic inflammatory processes, bronchial asthma, intestinal inflammatory diseases, gastπtes. duodemtes. gastric ulcers, duodenal ulcers, pneumonias and pleurisies, infections from adenovirus. baculovirus and in general supported by a viral agent. diseases characterised by acute and/or chrome inflammatory and/or degenerative processes of the central and/or peripheral nervous system, pancreatites. endomyocardites and ischaemic damage (myocardiac. retinal, cerebral and renal), urolithiases. nephrocalcinoses, hyperoxaluπa, hyperphosphatuπa. nephroalteration in the systemic and/or district arterial and/or venous pressure such as portal hypertension. vaginoses and vagimtes. procto-haemerrhoidal inflammations, prostates, sinusites and otites. conjunctivites. 16 gingivites. penodontopathy, anaphylactic phenomena and immunodeficiencies 13 Use according to any one of claims 5 to 12 wherein the bacteria are administered individually or in association with each other or with Lactobacillus acidophilus. Lactobacillus buchneπ . Lactobacillus casei . Lactobacillus catena forme. Lactobacillus cellobiosus. Lactobacillus cnspatus. Lactobacillus curvatus. Lactobacillus delbrueckn . Lactobacillus jensenn. Lactobacillus leichmami. Lactobacillus mutus. Lactobacillus plantarum. Lactobacillus rogosae, Lactobacillus salivanus. Bifidobactenum adolescentis. Bifidobactenum angulatum. Bifidobactenum bifidum. Bifidobactenum breve. Bifidobactenum catenulatum, Bifidobactenum dentium. Bifidobactenum enksonn . Bifidobactenum mfantis. Bifidobactenum longum. Bifidobactenum plantarum. Bifidobactenum pseudo-catenulatu . Bifidobactenum pseudolongu . Streptococcus lactis. Streptococcus raffwolactis. Streptococcus thermophilus. Acidammococcus fermenta, Cytophaga fermentans. Rhodoferax fermentans. Cellulo onas fermentans and Zymomonas obilis and/or in association with arginine deiminase, sphingomyelinase or other enzymes, with cortisone. anti-inflammatory. inmuno-modulant, cytostatic. lmmunological . endocrmological. vascular. anaesthetic. and vasodilatory drugs, growth factors, cytokines. ceramides. vitamins and minerals, lipids, ammo acids and carbohydrates, formulations for enteric use and dietetic, prebiotic or probiotic supplements, and with excipients commonly used in the pharmaceutical industry or in the foodstuffs/dietetic field. 14 Use according to any one of claims 5 to 13 wherein the bacteria are lyophilised or sonicated 15. A pharmaceutical composition which can be administered enterally, topically, rectally, nasally or parenterally. to induce 17 apoptosis and/or reduce an inflammatory reaction, which comprises a quantity of bacteria endowed with arginine deiminase effective to induce apoptosis and/or reduce an inflammatory reaction and/or produce a curative effect in intestinal malabsorption and in pancreatic insufficiency with modulation of the metabolic and/or nutritional state of the subject to be treated 16 A composition according to claim 15 wherein the bacteria are Gram-positive bacteria. 17 A composition according to claim 15 wherein the bacteria are Gram-negative bacteria. 18. A composition according to claim 15 wherein the bacteria are lactic bacteria. 19. A composition according to claim 18 wherein the lactic bacteria are selected from the species Lactobaci l lus brevis. Lactobaci l lus fermentum and Lactobaci l lus casei . 20. A composition according to claim 19 wherein the lactic bacteria belong to any one of the strains according to claims 1. 2 or 3. 21. A composition according to claim 19 wherein the lactic bacteria belong to the strain lactobaci l lus brevis CD2 deposited with the DSM - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. Brunswick, Germany, under the access number DSM 11988. 22. A composition according to any one of claims 15 to 21 wherein the bacteria are lyophilised or sonicated 18 23 A composition according to any one of claims 15 to 22 wherein the concentration of the bacteria is from lxlO 1 CFU to lxlO 13 CFU per gram of composition 24 A composition according to any one of claims 15 to 23 for use in the prevention and treatment of tumours in general and in particular colon-rectal cancer, cancer of the liver, gliomae. neuroblastomae. squa ocellular oral carcinoma, lymphoid tumours, cancer of the prostate gland cancer of the bladder, cancer of the breast. cancer of the pleura and the peritoneum, serious myasthema. systemic lupus erythematosus . and other auto-immune diseases including those of the thyroid, diseases characterised by acute and/or chronic inflammatory processes, bronchial asthma, intestinal inflammatory diseases, gastπtes. duodemtes. gastric ulcers, duodenal ulcers. pneumonias and pleurisies, infections from adenovirus. baculovirus and in general supported by a viral agent, diseases characterised by acute and/or chrome inflammatory and/or degenerative processes of the central and/or peripheral nervous system, pancreatites. endomyocardites and ischaemic damage (myocardiac. retinal, cerebral and renal). urolithiases. nephrocalcinoses, hyperoxaluπa, hyperphosphatuπa. nephroalteration in the systemic and/or district arterial and/or venous pressure such as portal hypertension, vaginoses and vagmites. procto- haemerrhoidal inflammations, prostates. sinusites and otites. conjunctivites. gingivites. penodontopathy. anaphylactic phenomena and immunodeficiencies 25. A composition according to any one of claims 15 to 24 wherein the bacteria are administered individually or in association with each other or with Lactobaci l lus acidophi lus. Lactobaci l lus buchnen . Lactobaci llus casei . Lactobaci llus catenaforme. Lactobaci llus cellobwsus. Lactobaci l lus enspatus. Lactobaci l lus curvatus. Lactobaci llus delbrueckn Lactobaci llus ensenn Lactobaci llus leichmann , Lactobaci l lus m utus. Lactobaci l lus plantarum. 19 Lactobaci l lus rogosae. Lactobaci l lus sa livanus. Bifidobactenum adolescentis. Bi fidobactenum angulatu . Bifidobactenum bifidum. Bi fidobactenum breve. Bi fidobactenum catenulatum. Bifidobactenum dentium. Bifidobactenum eriksonn . Bifi obactenum mfantis. Bi fidobactenum longum. Bi fidobactenum plantarum. Bi fidobactenum pseudo -catenulatum, Bi fidobactenum pseudolongum. Streptococcus lactis. Streptococcus raffmolactis. Streptococcus thermophi lus. Acidammococcus fermenta. Cytophaga fermentans. Rhodoferax fermentans. Cel lulomonas fermentans and Zymo onas mobi l is or in association with arginine deiminase. sphingomyelmase or other enzymes, with cortisone, anti-inflammatory, immuno-modulant. cytostatic, imunological , endocπnological , vascular, anaesthetic, and vasodilatory drugs, growth factors, cytokines. ceramides. vitamins and minerals, lipids. amino acids and carbohydrates, formulations for enteric use and dietetic. prebiotic or probiotic supplements, and with excipients commonly used in the pharmaceutical industry or in the foodstuffs/dietetic field.

Inventors: DE SIMONE CLAUDIO, DE SIMONE, CLAUDIO
Applicants: MENDES SRL, SIMONE CLAUDIO DE, DE SIMONE, CLAUDIO, MENDES S.R.L.
Application year: 1998
Main classification: C12N9
IPC codes: A61K35, A61K38, A61P29, A61P35, A61P43, C12N1, C12N9, C12R1